Literature DB >> 28978690

Aryl Hydrocarbon Receptor Activation Suppresses EBF1 and PAX5 and Impairs Human B Lymphopoiesis.

Jinpeng Li1,2, Sudin Bhattacharya2,3,4,5, Jiajun Zhou2,6, Ashwini S Phadnis-Moghe2, Robert B Crawford2,4, Norbert E Kaminski7,4.   

Abstract

Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that mediates biological responses to endogenous and environmental chemical cues. Increasing evidence shows that the AHR plays physiological roles in regulating development, homeostasis, and function of a variety of cell lineages in the immune system. However, the role of AHR in human B cell development has not been investigated. Toward this end, an in vitro feeder-free human B cell developmental model system was employed using human cord blood CD34+ hematopoietic stem/progenitor cells. Using this model, we found that AHR activation by the high-affinity ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin significantly suppressed the generation of early B cells and pro-B cells from hematopoietic stem/progenitor cells, indicating the impairment of B cell lineage specification and commitment. Addition of an AHR antagonist reversed 2,3,7,8-tetrachlorodibenzo-p-dioxin-elicited suppression of early B and pro-B cells, suggesting a role of AHR in regulating B lymphopoiesis. Gene expression analysis revealed a significant decrease in the messenger RNA level of early B cell factor 1 (EBF1) and paired box 5, two critical transcription factors directing B cell lineage specification and commitment. Additionally, binding of the ligand-activated AHR to the putative dioxin response elements in the EBF1 promoter was demonstrated by EMSAs and chromatin immunoprecipitation analysis, suggesting transcriptional regulation of EBF1 by AHR. Taken together, this study demonstrates a role for the AHR in regulating human B cell development, and it suggests that transcriptional alterations of EBF1 by the AHR are involved in the underlying mechanism.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28978690      PMCID: PMC5679724          DOI: 10.4049/jimmunol.1700289

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Aryl hydrocarbon receptor activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin impairs human B lymphopoiesis.

Authors:  Jinpeng Li; Ashwini S Phadnis-Moghe; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicology       Date:  2016-12-31       Impact factor: 4.221

2.  Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.

Authors:  Anthony E Boitano; Jian Wang; Russell Romeo; Laure C Bouchez; Albert E Parker; Sue E Sutton; John R Walker; Colin A Flaveny; Gary H Perdew; Michael S Denison; Peter G Schultz; Michael P Cooke
Journal:  Science       Date:  2010-08-05       Impact factor: 47.728

3.  The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells.

Authors:  Ju Qiu; Jennifer J Heller; Xiaohuan Guo; Zong-ming E Chen; Kamonwan Fish; Yang-Xin Fu; Liang Zhou
Journal:  Immunity       Date:  2011-12-15       Impact factor: 31.745

4.  Failure of B-cell differentiation in mice lacking the transcription factor EBF.

Authors:  H Lin; R Grosschedl
Journal:  Nature       Date:  1995-07-20       Impact factor: 49.962

5.  Aryl hydrocarbon receptor control of a disease tolerance defence pathway.

Authors:  Alban Bessede; Marco Gargaro; Maria T Pallotta; Davide Matino; Giuseppe Servillo; Cinzia Brunacci; Silvio Bicciato; Emilia M C Mazza; Antonio Macchiarulo; Carmine Vacca; Rossana Iannitti; Luciana Tissi; Claudia Volpi; Maria L Belladonna; Ciriana Orabona; Roberta Bianchi; Tobias V Lanz; Michael Platten; Maria A Della Fazia; Danilo Piobbico; Teresa Zelante; Hiroshi Funakoshi; Toshikazu Nakamura; David Gilot; Michael S Denison; Gilles J Guillemin; James B DuHadaway; George C Prendergast; Richard Metz; Michel Geffard; Louis Boon; Matteo Pirro; Alfonso Iorio; Bernard Veyret; Luigina Romani; Ursula Grohmann; Francesca Fallarino; Paolo Puccetti
Journal:  Nature       Date:  2014-07-10       Impact factor: 49.962

6.  E2A proteins promote development of lymphoid-primed multipotent progenitors.

Authors:  Sheila Dias; Robert Månsson; Sandeep Gurbuxani; Mikael Sigvardsson; Barbara L Kee
Journal:  Immunity       Date:  2008-07-31       Impact factor: 31.745

7.  High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.

Authors:  R P Kuiper; E F P M Schoenmakers; S V van Reijmersdal; J Y Hehir-Kwa; A Geurts van Kessel; F N van Leeuwen; P M Hoogerbrugge
Journal:  Leukemia       Date:  2007-04-19       Impact factor: 11.528

8.  Dioxin- and Ah receptor-dependent protein binding to xenobiotic responsive elements and G-rich DNA studied by in vivo footprinting.

Authors:  A J Watson; O Hankinson
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

Review 9.  Toward understanding the role of aryl hydrocarbon receptor in the immune system: current progress and future trends.

Authors:  Hamza Hanieh
Journal:  Biomed Res Int       Date:  2014-01-06       Impact factor: 3.411

Review 10.  The role of the aryl hydrocarbon receptor in normal and malignant B cell development.

Authors:  David H Sherr; Stefano Monti
Journal:  Semin Immunopathol       Date:  2013-08-13       Impact factor: 9.623

View more
  16 in total

Review 1.  Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis.

Authors:  Bert A 't Hart
Journal:  Primate Biol       Date:  2019-05-10

2.  Lymphocyte-Specific Protein Tyrosine Kinase (LCK) is Involved in the Aryl Hydrocarbon Receptor-Mediated Impairment of Immunoglobulin Secretion in Human Primary B Cells.

Authors:  Jiajun Zhou; Qiang Zhang; Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2018-10-01       Impact factor: 4.849

Review 3.  Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases.

Authors:  Wenjing Yang; Yingzi Cong
Journal:  Cell Mol Immunol       Date:  2021-03-11       Impact factor: 11.530

4.  TCDD attenuates EAE through induction of FasL on B cells and inhibition of IgG production.

Authors:  Evangel Kummari; Erin Rushing; Ashleigh Nicaise; Amye McDonald; Barbara L F Kaplan
Journal:  Toxicology       Date:  2020-11-28       Impact factor: 4.221

Review 5.  Regulation of Innate Lymphoid Cells by Aryl Hydrocarbon Receptor.

Authors:  Shiyang Li; John W Bostick; Liang Zhou
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

Review 6.  Effects of environmental stressors on stem cells.

Authors:  Jessica R Worley; Graham C Parker
Journal:  World J Stem Cells       Date:  2019-09-26       Impact factor: 5.326

Review 7.  Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells.

Authors:  Maxime Espi; Laetitia Koppe; Denis Fouque; Olivier Thaunat
Journal:  Toxins (Basel)       Date:  2020-05-06       Impact factor: 4.546

8.  Identification of a Sensitive Human Immunological Target of Aryl Hydrocarbon Receptor Activation: CD5+ Innate-Like B Cells.

Authors:  Lance K Blevins; Jiajun Zhou; Robert B Crawford; Norbert E Kaminski
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

Review 9.  RNA Flow Cytometry for the Study of T Cell Metabolism.

Authors:  Alessandra Rossi; Ilenia Pacella; Silvia Piconese
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

10.  AHR Signaling Dampens Inflammatory Signature in Neonatal Skin γδ T Cells.

Authors:  Katja Merches; Alfonso Schiavi; Heike Weighardt; Swantje Steinwachs; Nadine Teichweyde; Irmgard Förster; Katrin Hochrath; Beatrix Schumak; Natascia Ventura; Patrick Petzsch; Karl Köhrer; Charlotte Esser
Journal:  Int J Mol Sci       Date:  2020-03-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.